Kai Breuhahn

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3574409/publications.pdf

Version: 2024-02-01

89 papers	4,496 citations	94269 37 h-index	106150 65 g-index
92 all docs	92 docs citations	92 times ranked	7867 citing authors

#	Article	IF	Citations
1	Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yesâ€Associated Protein 1 Activation and Transient Expansion of Stemâ€Like Cancer Cells. Hepatology Communications, 2022, 6, 1140-1156.	2.0	6
2	HELLS Is Negatively Regulated by Wild-Type P53 in Liver Cancer by a Mechanism Involving P21 and FOXM1. Cancers, 2022, 14, 459.	1.7	6
3	Non-canonical NF-Î°B signaling induces proliferation in primary liver cancer. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.2	0
4	Direct interaction of the oncogenes YAP and TAZ with the transcription factor HNF1B in hepatocellular carcinoma. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.2	0
5	STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma. Cancers, 2022, 14, 1154.	1.7	11
6	LINC00152 Drives a Competing Endogenous RNA Network in Human Hepatocellular Carcinoma. Cells, 2022, 11, 1528.	1.8	6
7	YAPâ€induced Ccl2 expression is associated with a switch in hepatic macrophage identity and vascular remodelling in liver cancer. Liver International, 2021, 41, 3011-3023.	1.9	17
8	Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer. Gut, 2021, , gutjnl-2021-325405.	6.1	15
9	Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma. BMC Cancer, 2021, 21, 1079.	1.1	14
10	TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells. Cancer Letters, 2020, 473, 164-175.	3.2	39
11	YAP Orchestrates Heterotypic Endothelial Cell Communication via HGF/c-MET Signaling in Liver Tumorigenesis. Cancer Research, 2020, 80, 5502-5514.	0.4	31
12	Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis. Cell Communication and Signaling, 2020, 18, 166.	2.7	21
13	A dual role for hepatocyte-intrinsic canonical NF-Î°B signalingÂinÂvirus control. Journal of Hepatology, 2020, 72, 960-975.	1.8	18
14	Nucleoporin Nup155 is part of the p53 network in liver cancer. Nature Communications, 2019, 10, 2147.	5.8	29
15	YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells. Oncogene, 2019, 38, 5541-5550.	2.6	45
16	Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice. Gastroenterology, 2019, 156, 1190-1205.e14.	0.6	19
17	Karyopherin Î±2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer. Cell Communication and Signaling, 2019, 17, 159.	2.7	29
18	Editorial: Systems Biology and Bioinformatics in Gastroenterology and Hepatology. Frontiers in Physiology, 2019, 10, 1438.	1.3	0

#	Article	IF	Citations
19	Epigenetically Regulated Chromosome 14q32 miRNA Cluster Induces Metastasis and Predicts Poor Prognosis in Lung Adenocarcinoma Patients. Molecular Cancer Research, 2018, 16, 390-402.	1.5	63
20	Cytoplasmic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness. Hepatology, 2018, 67, 1842-1856.	3.6	48
21	Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma. Frontiers in Physiology, 2018, 9, 1918.	1.3	12
22	Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer. Gastroenterology, 2017, 152, 2037-2051.e22.	0.6	118
23	TTCA: an R package for the identification of differentially expressed genes in time course microarray data. BMC Bioinformatics, 2017, 18, 33.	1.2	16
24	Proteomic Analysis Reveals GMP Synthetase as p53 Repression Target in Liver Cancer. American Journal of Pathology, 2017, 187, 228-235.	1.9	26
25	An individual-based model for collective cancer cell migration explains speed dynamics and phenotype variability in response to growth factors. Npj Systems Biology and Applications, 2017, 3, 5.	1.4	29
26	A20/TNFAIP3 Discriminates Tumor Necrosis Factor (TNF)-Induced NF-Î²B from JNK Pathway Activation in Hepatocytes. Frontiers in Physiology, 2017, 8, 610.	1.3	16
27	FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas. PLoS Genetics, 2017, 13, e1007097.	1.5	48
28	MicroRNAs are key regulators of hepatocellular carcinoma (HCC) cell disseminationâ€"what we learned from microRNA-494. Hepatobiliary Surgery and Nutrition, 2016, 5, 372-376.	0.7	6
29	Quantitative estimation of tumor cellularity based on histology data. , 2016, , .		1
30	PI3K/AKT/mTORâ€dependent stabilization of oncogenic farâ€upstream element binding proteins in hepatocellular carcinoma cells. Hepatology, 2016, 63, 813-826.	3.6	52
31	Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukinâ€6 signaling in hepatocellular carcinoma. Hepatology, 2016, 64, 828-842.	3.6	29
32	Inducing Differentiation of Premalignant Hepatic Cells as a Novel Therapeutic Strategy in Hepatocarcinoma. Cancer Research, 2016, 76, 5550-5561.	0.4	15
33	The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells. OncoImmunology, 2016, 5, e1116674.	2.1	39
34	Tumor microvasculature in lung cancer and diffusion-weighted MRI: Preliminary results. , 2016, , .		0
35	Directed random walks and constraint programming reveal active pathways in hepatocyte growth factor signaling. FEBS Journal, 2016, 283, 350-360.	2.2	5
36	Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation. International Journal of Oncology, 2016, 48, 1679-1687.	1.4	11

#	Article	IF	Citations
37	Cellular apoptosis susceptibility (CAS) is linked to integrin Î²1 and required for tumor cell migration and invasion in hepatocellular carcinoma (HCC). Oncotarget, 2016, 7, 22883-22892.	0.8	18
38	Implementation of systems theory in liver cancer research. Hepatic Oncology, 2015, 2, 9-11.	4.2	0
39	Concomitant expression of far upstream element (<scp>FUSE</scp>) binding protein (<scp>FBP</scp>) interacting repressor (<scp>FIR</scp>) and its splice variants induce migration and invasion of nonâ€small cell lung cancer (<scp>NSCLC</scp>) cells. Journal of Pathology, 2015, 237, 390-401.	2.1	32
40	Curcumin effectively inhibits oncogenic NF-ÎºB signaling and restrains stemness features in liver cancer. Journal of Hepatology, 2015, 63, 661-669.	1.8	237
41	SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. Oncotarget, 2015, 6, 2222-2234.	0.8	27
42	Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma. Hepatology, 2014, 59, 1900-1911.	3.6	155
43	Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma. Hepatology, 2014, 60, 1241-1250.	3.6	39
44	Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Hepatology, 2014, 59, 544-554.	3.6	97
45	Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment. Cancer Discovery, 2014, 4, 730-743.	7.7	165
46	Prosurvival function of the cellular apoptosis susceptibility/importin-Î±1 transport cycle is repressed by p53 in liver cancer. Hepatology, 2014, 60, 884-895.	3.6	29
47	Nuclear Expression of the Deubiquitinase CYLD Is Associated with Improved Survival in Human Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e110591.	1.1	12
48	Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood, 2013, 122, 684-693.	0.6	109
49	Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma. BMC Cancer, 2013, 13, 532.	1.1	23
50	Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1). Hepatology, 2013, 58, 1703-1712.	3.6	208
51	Yes-Associated Protein Up-regulates Jagged-1 and Activates the NOTCH Pathway in Human Hepatocellular Carcinoma. Gastroenterology, 2013, 144, 1530-1542.e12.	0.6	278
52	Endothelial transdifferentiation in hepatocellular carcinoma: loss of Stabilinâ€2 expression in periâ€tumourous liver correlates with increased survival. Liver International, 2013, 33, 1428-1440.	1.9	49
53	Endothelial plasticity governs the siteâ€specific leukocyte recruitment in hepatocellular cancer. International Journal of Cancer, 2013, 133, 2372-2382.	2.3	4
54	Comparative Analysis of TGF-Î²/Smad Signaling Dependent Cytostasis in Human Hepatocellular Carcinoma Cell Lines. PLoS ONE, 2013, 8, e72252.	1.1	59

#	Article	IF	Citations
55	Stathmin Regulates Keratinocyte Proliferation and Migration during Cutaneous Regeneration. PLoS ONE, 2013, 8, e75075.	1.1	16
56	Molecular Pathology of Liver Tumors. , 2013, , 43-63.		3
57	A Systems Biology Study on NFÎºB Signaling in Primary Mouse Hepatocytes. Frontiers in Physiology, 2012, 3, 466.	1.3	9
58	Nuclear Pore Component Nup98 Is a Potential Tumor Suppressor and Regulates Posttranscriptional Expression of Select p53 Target Genes. Molecular Cell, 2012, 48, 799-810.	4.5	57
59	Transcriptional regulators in hepatocarcinogenesis â€“ Key integrators of malignant transformation. Journal of Hepatology, 2012, 57, 186-195.	1.8	20
60	Nuclear accumulation of seven in absentia homologueâ€2 supports motility and proliferation of liver cancer cells. International Journal of Cancer, 2012, 131, 2016-2026.	2.3	21
61	Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP. Developmental Biology, 2012, 367, 187-196.	0.9	126
62	Nuclear expression of the ubiquitin ligase seven in absentia homolog (SIAH)-1 induces proliferation and migration of liver cancer cells. Journal of Hepatology, 2011, 55, 1049-1057.	1.8	52
63	Strategies for hepatocellular carcinoma therapy and diagnostics: Lessons learned from high throughput and profiling approaches. Hepatology, 2011, 53, 2112-2121.	3.6	49
64	Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells. Oral and Maxillofacial Surgery, 2010, 14, 53-57.	0.6	6
65	Down-regulation of tumor suppressor a kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms. Hepatology, 2010, 52, 2023-2033.	3.6	61
66	Lipid droplet-associated PAT-proteins show frequent and differential expression in neoplastic steatogenesis. Modern Pathology, 2010, 23, 480-492.	2.9	131
67	A Cellular View of Nf2 in Liver Homeostasis and Tumorigenesis. Developmental Cell, 2010, 19, 363-364.	3.1	5
68	The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells. Journal of Clinical Investigation, 2010, 120, 3820-3833.	3.9	45
69	Coordinated Expression of Stathmin Family Members by Far Upstream Sequence Element-Binding Protein-1 Increases Motility in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2009, 69, 2234-2243.	0.4	85
70	Overexpression of far upstream element binding proteins: A mechanism regulating proliferation and migration in liver cancer cells. Hepatology, 2009, 50, 1130-1139.	3.6	92
71	S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology, 2009, 50, 1251-1262.	3.6	129
72	AP-1-Controlled Hepatocyte Growth Factor Activation Promotes Keratinocyte Migration via CEACAM1 and Urokinase Plasminogen Activator/Urokinase Plasminogen Receptor. Journal of Investigative Dermatology, 2009, 129, 1140-1148.	0.3	17

#	Article	IF	Citations
73	Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology, 2008, 48, 146-156.	3.6	100
74	Quantitative Analysis of Gene Expression Relative to 18S rRNA in Carcinoma Samples Using the LightCyclerÂ® Instrument and a SYBR GreenI-based Assay: Determining FAT10 mRNA Levels in Hepatocellular Carcinoma. Methods in Molecular Biology, 2008, 429, 59-72.	0.4	11
75	Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World Journal of Gastroenterology, 2008, 14, 1690.	1.4	67
76	Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology, 2007, 46, 759-768.	3.6	103
77	Non-specific effects of siRNAs on tumor cells with implications on therapeutic applicability using RNA interference. Pathology and Oncology Research, 2007, 13, 84-90.	0.9	18
78	Ex vivo analysis of antineoplastic agents in precision-cut tissue slices of human origin: effects of cyclooxygenase-2 inhibition in hepatocellular carcinoma. Liver International, 2006, 26, 604-612.	1.9	23
79	Expression of epithelial cellular adhesion molecule (Ep-CAM) in chronic (necro-)inflammatory liver diseases and hepatocellular carcinoma. Hepatology Research, 2006, 34, 50-56.	1.8	22
80	The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in Cancer Treatment. Current Cancer Therapy Reviews, 2006, 2, 157-167.	0.2	5
81	Cyclooxygenase-2 Inhibition Induces Apoptosis Signaling via Death Receptors and Mitochondria in Hepatocellular Carcinoma. Cancer Research, 2006, 66, 7059-7066.	0.4	151
82	Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis, 2004, 25, 1193-1199.	1.3	75
83	Factors of transforming growth factor ? signalling are co-regulated in human hepatocellular carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 589-596.	1.4	29
84	Molecular Profiling of Human Hepatocellular Carcinoma Defines Mutually Exclusive Interferon Regulation and Insulin-Like Growth Factor II Overexpression. Cancer Research, 2004, 64, 6058-6064.	0.4	119
85	Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes. Journal of Pathology, 2003, 201, 250-259.	2.1	107
86	Molecular pathogenesis of human hepatocellular carcinoma. Advances in Cancer Research, 2002, 86, 67-112.	1.9	48
87	Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology, 2002, 36, 885-894.	3.6	143
88	Keratinocyte-Derived Granulocyte-Macrophage Colony Stimulating Factor Accelerates Wound Healing: Stimulation of Keratinocyte Proliferation, Granulation Tissue Formation, and Vascularization. Journal of Investigative Dermatology, 2001, 117, 1382-1390.	0.3	142
89	The designer cytokine hyper-IL-6 mediates growth inhibition and GMâ€“CSF-dependent rejection of B16 melanoma cells. Oncogene, 2001, 20, 972-979.	2.6	27